HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Qureshi, Abid ^a   Thakur, Nishant ^a   Kumar, Manoj ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALANINE; AMIDE; AMINE; ANTIVIRUS AGENT; ASPARTIC ACID; CD4 ANTIGEN; CYSTEINE; GLUTAMINE; GLYCINE; HISTIDINE; INTEGRASE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; TYROSINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID COMPOSITION; ARTICLE; BIOAVAILABILITY; CELL FUSION; COMPUTER PROGRAM; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; PROTEIN BINDING; PROTEIN DEGRADATION; REFERENCE DATABASE; VALIDATION PROCESS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; CELL LINE; DATABASES, PROTEIN; HIV; INTERNET; MODELS, MOLECULAR; PEPTIDES; USER-COMPUTER INTERFACE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84872851002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054908     Document Type: Article

References (34)

1. Weiss RA, (1993) How does HIV cause AIDS? Science 260: 1273-1279.
2. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471-484.
3. Tyagi A, Ahmed F, Thakur N, Sharma A, Raghava GP, et al. (2011) HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One 6: e25917.
4. Hawkins T, (2010) Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 85: 201-209.
5. Castel G, Chteoui M, Heyd B, Tordo N, (2011) Phage display of combinatorial peptide libraries: application to antiviral research. Molecules 16: 3499-3518.
6. Pang W, Tam SC, Zheng YT, (2009) Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother 20: 1-18.
7. Rausch DM, Hwang KM, Padgett M, Voltz AH, Rivas A, et al. (1990) Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents. Ann N Y Acad Sci 616: 125-148.
8. Jin BS, Ryu JR, Ahn K, Yu YG, (2000) Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 16: 1797-1804.
9. Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, et al. (2009) A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. J Biol Chem 284: 254-264.
10. Gleenberg IO, Herschhorn A, Hizi A, (2007) Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J Mol Biol 369: 1230-1243.
11. Li HY, Zawahir Z, Song LD, Long YQ, Neamati N, (2006) Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. J Med Chem 49: 4477-4486.
12. Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A, (2005) Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J Biol Chem 280: 21987-21996.
13. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR, (1998) Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry 37: 2105-2110.
14. Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, et al. (1996) The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res 30: 155-170.
15. Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, et al. (2002) Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr. J Biol Chem 277: 48816-48826.
16. Boussard C, Doyle VE, Mahmood N, Klimkait T, Pritchard M, et al. (2002) Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. Eur J Med Chem 37: 883-890.
17. Fjell CD, Hiss JA, Hancock RE, Schneider G, (2012) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11: 37-51.
18. Ashkenazi A, Wexler-Cohen Y, Shai Y, (2011) Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim Biophys Acta 1808: 2352-2358.
19. Liu Z, Shan M, Li L, Lu L, Meng S, et al. (2011) In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 286: 3277-3287.
20. Chong H, Yao X, Zhang C, Cai L, Cui S, et al. (2012) Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 7: e32599.
21. Huther A, Dietrich U, (2007) The emergence of peptides as therapeutic drugs for the inhibition of HIV-1. AIDS Rev 9: 208-217.
22. Wang G, Li X, Wang Z, (2009) APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 37: D933-937.
23. Thomas S, Karnik S, Barai RS, Jayaraman VK, Idicula-Thomas S, (2010) CAMP: a useful resource for research on antimicrobial peptides. Nucleic Acids Res 38: D774-780.
24. Thakur N, Qureshi A, Kumar M, (2012) AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res 40: W199-204.
25. Kawashima S, Kanehisa M, (2000) AAindex: amino acid index database. Nucleic Acids Res 28: 374.
26. Kaur H, Garg A, Raghava GP, (2007) PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. Protein Pept Lett 14: 626-631.
27. Stefano KA, Collman R, Kolson D, Hoxie J, Nathanson N, et al. (1993) Replication of a macrophage-tropic strain of human immunodeficiency virus type 1 (HIV-1) in a hybrid cell line, CEMx174, suggests that cellular accessory molecules are required for HIV-1 entry. J Virol 67: 6707-6715.
28. Gentilucci L, De Marco R, Cerisoli L, (2010) Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 16: 3185-3203.
29. Thakur N, Qureshi A, Kumar M, (2012) VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res 40: D230-236.
30. Jiang H, Xu Y, Li L, Weng L, Wang Q, et al. (2011) Inhibition of influenza virus replication by constrained peptides targeting nucleoprotein. Antivir Chem Chemother 22: 119-130.
31. Real E, Rain JC, Battaglia V, Jallet C, Perrin P, et al. (2004) Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J Virol 78: 7410-7417.
32. Este JA, Cihlar T, (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Res 85: 25-33.
33. Kaushik-Basu N, Basu A, Harris D, (2008) Peptide inhibition of HIV-1: current status and future potential. BioDrugs 22: 161-175.
34. Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS, (2002) Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A 99: 14664-14669.